The investigators also propose to evaluate potential assessment tools to determine whether they are relevant for monitoring this population, either routinely or for future clinical trials. The investigators also aim to collect the total costs associated with ASI in order to propose a first prospective medico-economic study in France. conditions: Spinal Muscular Atrophy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, longitudinal, multicenter, international study primaryPurpose: OTHER masking: NONE count: 60 type: ESTIMATED name: evaluation of muscle function name: First-line cognitive assessment name: second-line cognitive assessment name: Cardiac evaluation name: MRI name: Assessment of activity and muscle fatigue name: Assessment of bulbar function name: Evaluation of body composition and metabolism name: Questionnaires name: Biocollection name: Skinfold measurement measure: Markers of disease progression and description of different phenotypes, at : muscular and functional measure: Markers of disease progression and description of different phenotypes, at : muscular and functional measure: Markers of disease progression and description of different phenotypes, at : muscular and functional measure: Markers of disease progression and description of different phenotypes, at : muscular and functional measure: Markers of disease progression and description of different phenotypes, at : muscular and functional measure: Markers of disease progression and description of different phenotypes, at : Fatigue measure: Markers of disease progression and description of different phenotypes, at : Fatigue measure: Markers of disease progression and description of different phenotypes, at : Fatigue measure: Markers of disease progression and description of different phenotypes, at Orthopaedic level measure: Markers of disease progression and description of different phenotypes, at Orthopaedic level measure: Markers of disease progression and description of different phenotypes, at Orthopaedic level measure: Markers of disease progression and description of different phenotypes, at the cognitive level: Vineland-II measure: Markers of disease progression and description of different phenotypes, at the cognitive level: Bayley-4 measure: Markers of disease progression and description of different phenotypes, at the cognitive level: BRIEF (Behavioral Rating Inventory of Executive Function) measure: Markers of disease progression and description of different phenotypes, at the cognitive level: Conners-3 measure: Markers of disease progression and description of different phenotypes, at the cognitive level: CELF-5 (Language and communication assessment battery) measure: Markers of disease progression and description of different phenotypes, at the cognitive level: EQ (Empathy quotient), AQ (Autism Quotient) measure: Markers of disease progression and description of different phenotypes, at the cognitive level: M-CHAT-R (Modified Checklist for Autism in Toddlers) measure: Markers of disease progression and description of different phenotypes, at the cognitive level: SRS-2 (Social Responsiveness Scale, Second Edition) measure: Markers of disease progression and description of different phenotypes, at the cognitive level: PVSE (Basic visuo-spatial perception) measure: Markers of disease progression and description of different phenotypes, at the brain level measure: Markers of disease progression and description of different phenotypes, at Cardiology level measure: Markers of disease progression and description of different phenotypes, at metabolic level : Anthropometric measurement trends measure: Markers of disease progression and description of different phenotypes, at metabolic level : measure: Markers of disease progression and description of different phenotypes, at metabolic level : fractures measure: Markers of disease progression and description of different phenotypes, at metabolic level : renal ultrasound measure: Markers of disease progression and description of different phenotypes, at metabolic level : Absorptiometry (DXA) measure: Markers of disease progression and description of different phenotypes, at metabolic level: Calorimetry measure: Markers of disease progression and description of different phenotypes, at metabolic level : Impedancemetry measure: Markers of disease progression and description of different phenotypes, at metabolic level : Fibroscan measure: Markers of disease progression and description of different phenotypes, at biological analysis measure: Markers of disease progression and description of different phenotypes, at In terms of quality of life and autonomy measure: Markers of disease progression and description of different phenotypes, at In terms of quality of life and autonomy measure: Markers of disease progression and description of different phenotypes, at respiratory level : Chest/head circumference ratio (PT/PC ratio) (up to 3 years) measure: Markers of disease progression and description of different phenotypes, at respiratory level : Chest/head circumference ratio (PT/PC ratio) measure: Markers of disease progression and description of different phenotypes, at respiratory level : O2 saturation and nocturnal TcPCO2 measure: Markers of disease progression and description of different phenotypes, at respiratory level: Respiratory function tests (≥ 6 years) measure: Markers of disease progression at respiratory level measure: Markers of disease progression and description of different phenotypes, at bulbar level (Evaluation of dysphagia and dysarthria): DDD-pNMD (Diagnostic list for Dysphagia and Dysarthria in pediatric NeuroMuscular Disorders) measure: Markers of disease progression and description of different phenotypes, at bulbar level (Evaluation of dysphagia and dysarthria): NdSSS (Neuromuscular Disease Swallowing Status Scale). measure: Markers of disease progression and description of different phenotypes, at the level of Characteristics at inclusion: age of patient measure: Markers of disease progression and description of different phenotypes, at the level of Characteristics at inclusion : patient gender measure: Markers of disease progression and description of different phenotypes, at the level of Characteristics at inclusion: SMA TYPE measure: Markers of disease progression and description of different phenotypes, at the level of Characteristics at inclusion: number of copy measure: Markers of disease progression and description of different phenotypes, at the level of Characteristics at inclusion: treatment sex: ALL minimumAge: 0 Years maximumAge: 16 Years stdAges: CHILD facility: Pediatric Rehabilitation Service - L'Escale Mother and Child Hospital city: Bron state: Rhone zip: 69500 country: France name: Laure LE GOFF, PI role: CONTACT phone: 04.72.12.95.04 phoneExt: +33 email: laure.le-goff@chu-lyon.fr name: Laure LE GOFF role: PRINCIPAL_INVESTIGATOR lat: 45.73333 lon: 4.91667 facility: CHRU of Brest city: Brest zip: 29609 country: France name: Juliette ROPARS, Dr role: CONTACT phone: 02.98.22.33.89 phoneExt: +33 email: Juliette.ropars@chu-brest.fr name: Juliette ROPARS, Dr role: PRINCIPAL_INVESTIGATOR lat: 48.3903 lon: -4.48628 facility: Pediatric Neurology and Resuscitation Raymond-Poincare Hospital city: Garche zip: 92380 country: France name: Susana QUIJANO-ROY, Pr role: CONTACT phone: 01.47.10.79.16 phoneExt: +33 email: Susana.quijano-roy@aphp.fr name: Susana QUIJANO-ROY, Pr role: PRINCIPAL_INVESTIGATOR lat: 49.39419 lon: 6.19818 facility: Pediatric Neurology Swynghedauw Hospital city: Lille zip: 59037 country: France name: Jean-Baptiste DAVION, Dr role: CONTACT phone: 03.20.44.58.31 phoneExt: +33 email: Jeanbaptiste.davion@chru-lille.fr name: Jean-Baptiste DAVION, Dr role: PRINCIPAL_INVESTIGATOR lat: 50.63297 lon: 3.05858 facility: Marseille University Hospital - Timone Hospital Department of Pediatric Neurology - Specialized Pediatrics and Child Medicine city: Marseille zip: 13005 country: France name: Brigitte CHABROL, Pr role: CONTACT phone: 04.91.38.68.08 phoneExt: +33 email: brigitte.chabrol@ap-hm.fr name: Brigitte CHABROL, Pr role: PRINCIPAL_INVESTIGATOR lat: 43.29551 lon: 5.38958 facility: I-Motion Pediatric Clinical Trial Platform Armand Trousseau Hospital city: Paris zip: 75012 country: France name: Andreea SEFERIAN, Dr role: CONTACT phone: 01.71.73.80.50 phoneExt: +33 email: a.seferian@institut-myologie.org name: Andreea SEFERIAN role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Hautepierre Hospital - Mother and Child Hospital city: Strasbourg zip: 67200 country: France name: Vincent LAUGEL, Pr role: CONTACT phone: 03.88.12.77.43 phoneExt: +33 email: vincent.laugel@chru-strasbourg.fr name: Vincent LAUGEL, Pr role: PRINCIPAL_INVESTIGATOR lat: 48.58392 lon: 7.74553 facility: Department of Pediatrics - Neurology and Infectious Diseases Toulouse University Hospital - Children's Hospital city: Toulouse zip: 31059 country: France name: Claude CANCES, Pr role: CONTACT phone: 05.34.55.74.08 phoneExt: +33 email: cances.c@chu-toulouse.fr name: Claude CANCES, Pr role: PRINCIPAL_INVESTIGATOR lat: 43.60426 lon: 1.44367 hasResults: False